Clinical Trials Browser

Phase 1/2 × Neoplasm Metastasis × Lenalidomide × Clear all

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1/2 Terminated

83 enrolled 31 charts

Neoplasm Metastasis

NCT01342172 2019-04-23

Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

Phase 1/2 Terminated

9 enrolled 9 charts

Urinary Bladder Neoplasms, Neoplasm Metastasis